Concordance Between ER, PR, HER2 neu Receptors Before and After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
Introducing neoadjuvant chemotherapy (NCT) in a breast cancer patient may be associated with changes in estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth hormone receptor 2 (HER2) status.
Main Authors: | Taha Heba F., Elfarargy Ola M., Salem Reham A., Mandour Doaa, Salem Amira A., Riad Mohamed |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2021-05-01
|
Series: | Forum of Clinical Oncology |
Subjects: | |
Online Access: | https://doi.org/10.2478/fco-2019-0021 |
Similar Items
-
Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers
by: Atif Ali Hashmi, et al.
Published: (2018-08-01) -
The Study of HER-2/neu, ER/PR Expression Using Immunohistochemistry (IHC) in the Iraqi Breast Cancer
by: Suhad Faisal Hatem, et al.
Published: (2016-06-01) -
Correlation of HER-2/neu Status with Estrogen (ER) & Progesterone (PR) Receptor in Breast Malignancies
by: Asma Rasheed, et al.
Published: (2020-12-01) -
A study on molecular subtype of breast carcinoma using ER, HER2, PR, and its relation with Ki67
by: Haricharan BV, et al.
Published: (2023-11-01) -
Evaluation of estrogen and progesterone receptors and Her-2 expression with grading in the fine-needle aspirates of patients with breast carcinoma
by: Pampa Ch Toi, et al.
Published: (2018-01-01)